

significant resistance genes, making the treatment options for clinical infection rather limited (Table S1). No transconjugants were obtained when using the transformants that only harboured pEC05-X4 or pEC12-X4 as donor strain, indicating that *tet(X4)*-carrying plasmids were not self-transferable. However, *tet(X4)*-positive transconjugants were obtained (transfer frequency $\sim 10^{-5}$) when introducing pEC12-MCR into the pEC05-X4- or pEC12-X4-carrying transformants and using these strains as donors for conjugation, which implied that pEC12-MCR could serve as a helper plasmid for the horizontal transfer of *tet(X4)*.²

In conclusion, we report two *E. coli* isolates that co-harboured *tet(X4)* and *mcr-1* of pig origin. These two isolates showed resistance to most antimicrobials including the last-resort antibiotics tigecycline and colistin. The role of a conjugative *mcr-1*-carrying plasmid aiding the transmission of a non-conjugative *tet(X4)*-bearing plasmid should be highlighted and requires further monitoring.

Funding

This study was funded by grants from the National Natural Science Foundation of China (31702297, 81861138051, 31930110 and 31802221), the Natural Science Foundation of Jiangsu Province (BK20160577 and BK20180054), the Jiangsu Agricultural Science and Technology Foundation [CX(19)2014], the National Agricultural Product Quality and Safety Risk Assessment (1420195121), the National Key Research and Development Program (2018YFD0501403) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Transparency declarations

None to declare.

Supplementary data

Table S1 and Figures S1 and S2 are available as [Supplementary data](#) at JAC Online.

References

- 1 He T, Wang R, Liu D *et al.* Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. *Nat Microbiol* 2019; **4**: 1450–6.
- 2 Sun J, Chen C, Cui CY *et al.* Plasmid-encoded *tet(X)* genes that confer high-level tigecycline resistance in *Escherichia coli*. *Nat Microbiol* 2019; **4**: 1457–64.
- 3 Bai L, Du P, Du Y *et al.* Detection of plasmid-mediated tigecycline-resistant gene *tet(X4)* in *Escherichia coli* from pork, Sichuan and Shandong Provinces, China, February 2019. *Euro Surveill* 2019; **24**: pii=1900340.
- 4 Chen C, Cui CY, Zhang Y *et al.* Emergence of mobile tigecycline resistance mechanism in *Escherichia coli* strains from migratory birds in China. *Emerg Microbes Infect* 2019; **8**: 1219–22.
- 5 Liu YY, Wang Y, Walsh TR *et al.* Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis* 2016; **16**: 161–8.
- 6 Li R, Xie M, Lv J *et al.* Complete genetic analysis of plasmids carrying *mcr-1* and other resistance genes in an *Escherichia coli* isolate of animal origin. *J Antimicrob Chemother* 2016; **72**: 696–9.
- 7 Tijet N, Faccone D, Rapoport M *et al.* Molecular characteristics of *mcr-1*-carrying plasmids and new *mcr-1* variant recovered from polyclonal clinical *Escherichia coli* from Argentina and Canada. *PLoS One* 2017; **12**: e0180347.
- 8 He T, Wei R, Zhang L *et al.* Characterization of NDM-5-positive extensively resistant *Escherichia coli* isolates from dairy cows. *Vet Microbiol* 2017; **207**: 153–8.
- 9 He T, Wang Y, Sun L *et al.* Occurrence and characterization of *bla*_{NDM-5}-positive *Klebsiella pneumoniae* isolates from dairy cows in Jiangsu, China. *J Antimicrob Chemother* 2017; **72**: 90–4.

J Antimicrob Chemother 2020; **75**: 766–768
doi:10.1093/jac/dkz470
Advance Access publication 9 December 2019

Employees of Swiss veterinary clinics colonized with epidemic clones of carbapenemase-producing *Escherichia coli*

Andrea Endimiani ^{1*}, Michael Brillhante^{2,3}, Odette J. Bernasconi¹, Vincent Perreten², Janne S. Schmidt⁴, Valentina Dazio⁵, Aurélien Nigg², Stefanie Gobeli Brawand², Stefan P. Kuster⁶, Simone Schuller^{5†} and Barbara Willi^{4†}

¹Institute for Infectious Diseases, University of Bern, Bern, Switzerland; ²Institute of Veterinary Bacteriology, University of Bern, Bern, Switzerland; ³Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland; ⁴Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland; ⁵Division of Small Animal Internal Medicine, Department of Clinical Veterinary Medicine, University of Bern, Bern, Switzerland; ⁶Division of Infectious Diseases and Hospital Epidemiology, University and University Hospital of Zurich, Zurich, Switzerland

*Corresponding author. E-mail: andrea.endimiani@ifik.unibe.ch or aendimiani@gmail.com

†These authors contributed equally.

Sir,

The global spread of carbapenemase-producing Enterobacterales (CPE) represents an alarming public health issue. Infections due to these difficult to treat bacteria are associated with high morbidity and mortality rates. Moreover, subjects infected and/or colonized at the intestinal level can transmit their CPE to other people and may contribute to their diffusion in non-human settings.¹ Nowadays, the threat of CPE has also been increasingly observed




Figure 1. Phylogenetic Neighbor-Joining trees of representative *E. coli* complete chromosomes available in GenBank (accessed on 5 August 2019) together with the strains recovered in this study. Trees were generated and drawn using SeqSphere+ (v. 6.0.2, Rindom GmbH) comparing the genes of the core genome (cgMLST) of all included strains using the parameters 'pairwise ignoring missing values and % columns difference'. For each strain, we show the GenBank accession number, strain name, host (sample), year and country of detection. (a) Comparison of 3281 genes for 27 ST410 *E. coli* strains (strains possessing *bla*_{OXA-181} are indicated in bold, whereas those possessing other carbapenemases are underlined). In red we show the *bla*_{OXA-181}-harbouring strain (Ec-042) recovered from the employee at clinic A, while in blue we show a representative strain (AR24.2b) responsible for the outbreak involving 21 pets at the same institution. (b) Comparison of 3595 genes for 24 ST167 *E. coli* strains (strains possessing *bla*_{NDM-5} are indicated in bold, whereas those possessing other carbapenemases are underlined). In red we show the *bla*_{NDM-5}-harbouring strain (Ec-050) recovered from the employee at clinic B, while in blue we show the strains detected in three dogs at the same institution. na, not available; GBR, Great Britain; KOR, South Korea. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.

among pets hospitalized at veterinary clinics. Frequently, the CPE isolated from these animals share the same carbapenemase genes and/or lineage of those found in humans.^{2,3} However, data regarding the possible transmission of CPE from hospitalized animals to veterinary staff in contact with them, or vice versa, are lacking.

In Switzerland, the prevalence of CPE in both human and animal settings is still low (www.anresis.ch). Nevertheless, we recently described 21 cases of hospital-acquired gut colonization due to a common ST410 *bla*_{OXA-181}-harbouring *Escherichia coli* (ST410-OXA-181-Ec) in dogs and cats; such cases occurred during May–August 2018 at a large Swiss companion animal hospital (clinic A).⁴ Moreover, at another veterinary hospital (clinic B), a case of wound infection due to an ST167 *bla*_{NDM-5}-possessing *E. coli* (ST167-NDM-5-Ec) occurred in a dog in February 2018 (strain 51008369SK1).⁵ In this institution (June–July 2018), we also identified this type of CPE in rectal swabs of two other hospitalized dogs (strains AR202.2 and AR216.2b; GenBank: CP043946–CP043949 and CP043942–CP043945, respectively). Based on these alarming data, we decided to explore the presence of CPE in the intestinal tract of veterinary employees.

Between June and October 2018, a total of 108 employees of three Swiss veterinary clinics (A, *n* = 46; B, *n* = 37; and C, *n* = 21) and one private practice (*n* = 4) voluntarily self-collected their stools. Written informed consent was obtained from all participants. The

study protocol was approved by the Ethics Committee of the Canton of Bern (KEK-BE No: 2018–00866).

Samples were enriched overnight in LB broth supplemented with cefuroxime and then plated on ChromID Carba (bioMérieux).⁶ Colonies were identified at the species level using MALDI-TOF MS (Bruker). MICs were determined using the microdilution Sensititre™ GN2F plate (Trek Diagnostic) and interpreted using the 2019 EUCAST criteria (www.eucast.org). Strains suspected of carbapenemase production (MICs of meropenem and/or ertapenem >0.125 mg/L and BlueCarba test positive) underwent WGS using both NovaSeq 6000 (Illumina) and MinION (Oxford Nanopore). The final assembly was annotated using the NCBI Prokaryotic Genome Annotation Pipeline.⁶ Contigs were analysed using the tools of the Center for Genomic Epidemiology (www.genomicepidemiology.org/). Core genome MLST (cgMLST) analysis was also performed to compare the recovered CPE with those available in the NCBI.⁴

Two employees (1.9%) were shown to be colonized at the gut level with CPE (Table S1, available as [Supplementary data](#) at JAC Online); one subject at clinic A carried ST410-OXA-181-Ec (strain Ec-042; GenBank: CP042934–CP042936) and one subject at clinic B carried ST167-NDM-5-Ec (strain Ec-050; GenBank: CP043227–CP043230). Based on these worrying results, hospital environment swabs were taken from clinic A (*n* = 182) and B (*n* = 200) during July–August 2018 and processed.⁶ Five carbapenemase-producing *E. coli*

(two ST410-OXA-181-*Ec* and three OXA-48 producers of ST155, ST641 and ST4038) were detected at clinic A (data not shown).

Ec-042 carried *bla*_{OXA-181} and *qnrS1* in a 51 kb IncX3 plasmid, while *bla*_{CMY-42} was in a 47 kb IncI1 element. The *bla*_{OXA-181}-carrying plasmid was indistinguishable from those previously found in the ST410-OXA-181-*Ec* strains isolated from the 21 colonized dogs and cats at clinic A (e.g. pAN-OXA-181)⁴ and almost identical (identity $\geq 99.9\%$) to others described worldwide (Figure S1). Moreover, cgMLST analysis showed that *Ec*-042 shared a very high genetic relatedness to clinic A's ST410-OXA-181-*Ec* strains (e.g. strain AR24.2b),⁴ but was also closely related to ST410 strains from gulls in the USA (Figure 1a).

Ec-050 possessed three main plasmids: a 99 kb IncFII/FIA/FIB plasmid harbouring *bla*_{NDM-5}, *aac(3)-IIa*, *aadA2*, *dfrA12*, *mph(A)*, *sul1* and *tet(A)*; a 71 kb IncFII plasmid with *bla*_{CMY-2} and *erm(B)*; and a 115 kb IncI1 plasmid possessing *bla*_{TEM-30}, *aadA1*, *floR*, *sul1/2* and *dfrA1* resistance genes. The *bla*_{NDM-5}-harbouring plasmid showed an identity $>99.9\%$ with those found in the ST167-NDM-5-*Ec* detected from the three dogs hospitalized at clinic B (strains 51008369SK1,⁵ AR202.2 and AR216.2b) and one found in Italy in a human strain (Figure S2). Furthermore, cgMLST analysis showed that *Ec*-050 was highly related to the above NDM-5-producing dog strains, but also clustered with others detected in different countries and hosts (Figure 1b).

To the best of our knowledge, this is the first time that veterinary hospital staff have been found to be colonized with CPE. Worryingly, the recovered strains shared high genetic relatedness to those detected among dogs and cats hospitalized in the same employees' institutions. We also note that in our previous survey conducted at clinic A during 2013–16, gut CPE carriers among the staff were not identified.⁷ This might indicate that acquisition of CPE among the personnel is relatively recent. However, whether the veterinarians introduced the CPE into the hospitals or became colonized while working with the colonized pets remains unknown.

In conclusion, this study revealed that the diffusion of very successful international epidemic CPE clones (e.g. ST410-OXA-181-*Ec* and ST167-NDM-5-*Ec*)^{4,8,9} in companion animal veterinary clinics not only compromised the outcome of infected animals, but emphasized that people working with pets can be colonized. These subjects might also contribute to the transmission and further expansion of these life-threatening bacteria to healthy people in the community. Therefore, as practised in human hospitals, veterinary institutions must urgently implement optimal infection control practices (e.g. efficient cleaning and disinfection procedures) to face this concerning public health phenomenon.¹⁰ Moreover, detection of CPE in companion animals should become notifiable as it is for people.

Acknowledgements

We thank Thomas Büdel, Mathieu Clément and Alexandra Collaud for technical assistance. We are grateful to all participants who kindly donated their stool samples.

Funding

This work was financed by the Swiss Federal Food Safety and Veterinary Office (FSVO grant no. 1.18.10 to S.S., B.W., S.G.B., A.E. and V.P.) and by the Swiss National Science Foundation (SNF grant no. 177378 within the NRP-72, 'National Research Programme, Antimicrobial Resistance' to A.E. and V.P.).

Transparency declarations

None to declare.

Supplementary data

Table S1 and Figures S1 and S2 are available as [Supplementary data](#) at JAC Online.

References

- Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. *J Infect Dis* 2017; **215** Suppl 1: S28–36.
- Pomba C, Rantala M, Greko C *et al.* Public health risk of antimicrobial resistance transfer from companion animals. *J Antimicrob Chemother* 2017; **72**: 957–68.
- Madec JY, Haenni M, Nordmann P *et al.* Extended-spectrum β -lactamase/AmpC- and carbapenemase-producing Enterobacteriaceae in animals: a threat for humans? *Clin Microbiol Infect* 2017; **23**: 826–33.
- Nigg A, Brillhante M, Dazio V *et al.* Shedding of OXA-181 carbapenemase-producing *Escherichia coli* from companion animals after hospitalisation in Switzerland: an outbreak in 2018. *Euro Surveill* 2019; **24**: pii=1900071.
- Peterhans S, Stevens MJA, Nuesch-Inderbinen M *et al.* First report of a *bla*_{NDM-5}-harbouring *Escherichia coli* ST167 isolated from a wound infection in a dog in Switzerland. *J Glob Antimicrob Resist* 2018; **15**: 226–7.
- Budel T, Kuenzli E, Clement M *et al.* Polyclonal gut colonization with extended-spectrum cephalosporin- and/or colistin-resistant Enterobacteriaceae: a normal status for hotel employees on the island of Zanzibar, Tanzania. *J Antimicrob Chemother* 2019; **74**: 2880–90.
- Pires J, Kuenzli E, Hauser C *et al.* Intestinal colonisation with extended-spectrum cephalosporin-resistant Enterobacteriaceae in different populations in Switzerland: prevalence, risk factors and molecular features. *J Glob Antimicrob Resist* 2018; **12**: 17–9.
- Mataseje LF, Boyd DA, Fuller J *et al.* Characterization of OXA-48-like carbapenemase producers in Canada, 2011–14. *J Antimicrob Chemother* 2018; **73**: 626–33.
- Giufre M, Errico G, Accogli M *et al.* Emergence of NDM-5-producing *Escherichia coli* sequence type 167 clone in Italy. *Int J Antimicrob Agents* 2018; **52**: 76–81.
- Walther B, Tedin K, Lübke-Becker A. Multidrug-resistant opportunistic pathogens challenging veterinary infection control. *Vet Microbiol* 2017; **200**: 71–8.